Skip to main content

Afreen Idris Shariff

Associate Professor of Medicine
Medicine, Endocrinology, Metabolism, and Nutrition

Overview


Afreen Shariff, MD is an endocrinologist with expertise in endocrine disease in cancer patients. She is the Director of the Duke Onco Endocrinology Program and an Associate Director for the Cancer Therapy Toxicity Program at the Duke Center for Cancer Immunotherapy. She holds a faculty appointment as an Associate Professor of Medicine in the Division of Endocrinology, Diabetes and Metabolism at Duke University School of Medicine.

Dr. Shariff completed her medical school in India from Deccan College of Medical Sciences, Internal Medicine training from East Carolina University’s Brody School of Medicine and fellowship in Endocrinology from Duke University School of Medicine. Her clinical work and research is focused on high value care for endocrine disease in cancer patients.

She was the founding chair the Oncoendocrinology Special Interest Group (SIG) at the Endocrine Society and influences global networking, clinical practice and education in the field of Oncoendocrinology. At Duke, Dr. Shariff's work includes developing interdisciplinary partnerships, creating the clinical infrastructure and framework needed for AI assisted clinical decision making to improve access and coordinated care for patients with cancer therapy related toxicities. She also hosts and produces the podcast series Checkpoint NOW that emphasizes shared decision making between oncologists and subspecialists.

Current Appointments & Affiliations


Associate Professor of Medicine · 2024 - Present Medicine, Endocrinology, Metabolism, and Nutrition, Medicine
Member of the Duke Cancer Institute · 2019 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published January 15, 2021
Checkpoint NOW podcast launch
Published November 13, 2020
What to Know If You’re Going to Buy Black Market Insulin
Published June 4, 2019
Checkpoint Immune Agents Trigger High-Risk Reaction in Patient with Cancer

View All News

Recent Publications


Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors.

Journal Article J Immunother Cancer · April 8, 2025 Ophthalmic immune-related adverse events (Eye-irAEs) from immune checkpoint inhibitors can cause visual morbidity. The absence of standardized definitions for Eye-irAEs not only impedes the development of evidence-based treatments but also progress in tran ... Full text Link to item Cite

Endocrinopathies Associated With Immune Checkpoint Inhibitor Use.

Journal Article Endocr Pract · June 2024 OBJECTIVE: To provide a clinical approach towards immune checkpoint inhibitor (ICI)-associated endocrinopathies, their link with cancer outcomes, factors which differentiate them from other immune related adverse events, and health systems innovation to im ... Full text Link to item Cite

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.

Journal Article J Immunother Cancer · April 10, 2024 With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most common and earliest to manifest, often ... Full text Link to item Cite
View All Publications

Education, Training & Certifications


University of Hyderabad (India) · 2008 M.B.B.S.